On January 30, 2026, Becton Dickinson & Co announced a stock distribution plan related to their BioSciences and Diagnostic Solutions business, with an exchange of 27.5159 Preferred Shares to retain control over common stock amid a Reverse Morris Trust transaction. This is a significant event for the company, indicating a strategic alignment but will be seen as neutral from an investor perspective.